ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KTWO / financials
UTMD (62) PDEX (54) STIM (28) PROF (40) ⌘ Pro Terminal →

K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$10.11 +0.20% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.09

K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $202.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KTWO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KTWO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, K2 Capital Acquisition Corporation Class A Ordinary Share (NASDAQ: KTWO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $10.11 (+0.20% 1D, market cap $202.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KTWO ranks #200 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KTWO compare to UTMD and PDEX in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), KTWO carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, UTMD (Utah Medical Products Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 26.9%, cap $216.7M) and PDEX (Pro-Dex Inc.) posts a D+ grade (54/100 RQD, P/E 22.2x, ROIC 23.2%, cap $186.1M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KTWO?
▼

Per KTWO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002086524), K2 Capital Acquisition Corporation Class A Ordinary Share generated $317.0K in revenue, $0 in net income, and $0 in free cash flow against $754.7K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.09 (-0.15%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 566.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510056
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D · Rk C+
Cash (10)Whales (10)SEC (13)Macro (14)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-0.9% Base Target
$12 Bull$10 Base$8 Bear
📬 FREE KTWO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KTWO)Realized 20D OHLCV Swing Band: ±1.8%
Deterministic 5-Pillar Attribution (56/100 Composite)
🔍 WHY KTWO SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+14/20 pts (25% of score)

FRED Regime × Technicals: 96% of 52W Range • RSI-14 at 49 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
48
Grade D$10.09+0.1% Next Q
Q2 (-2Q)
51
Grade C-$10.10-0.1% Next Q
Q3 (-1Q)
53
Grade C-$10.09+0.2% Next Q
Current
56
Grade D+$10.11-0.4% Hist 90D α
Trajectory: D (48) → D+ (56)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the KTWO Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, KTWO faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($10.09) or 200D SMA ($9.99) invalidates the momentum regime and cuts Target Base ($10.02) toward Bear Floor ($7.82).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KTWO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KTWO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 56%NO 44%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How KTWO Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$5.7M (566.2% FCF Margin)
Revenue$1.0MGross Profit $520.0K (52%)Cost of Sales $480.0KOp Profit $0 (0%)OpEx (R&D/SG&A) $520.0KNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY25
Rev $317.0K
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$317.0K52%0%$0$015%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KTWO)

  • ✓Walkthrough of KTWO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KTWO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.81%⚡ TESTING RESISTANCE
2026-11-03O $10.12H $10.12L $10.09C $10.11VOL 15.8K
RES: $10.12SUP: $9.96SMA50: $10.09SMA200: $9.99
$10.14$10.07$10.00$9.94$9.87RES $10.12SUP $9.96$10.112026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KTWO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KTWO Butterfly Map → + Track KTWO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KTWO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KTWO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KTWO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KTWO)

Health Care Rank #200 of 1015 ⚔️ UTMD vs KTWO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KTWO vs. UTMD, PDEX, STIM, PROF)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) ranks #200 by composite RQD confidence (56/100, grade D+) and #571 by equity capitalization ($202.2M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with KTWO at 56/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KTWO ACTIVE
K2 Capital Acquisition Corporation Class A Ordinary Share
D+ 56/100 — — — +0.20% $202.2M Benchmark Subject
UTMD
Utah Medical Products Inc.
C 62/100 — 57.1% 26.9% +3.64% $216.7M /utmd-vs-ktwo →
PDEX
Pro-Dex Inc.
D+ 54/100 22.2x 29.3% 23.2% -0.88% $186.1M /pdex-vs-ktwo →
STIM
Neuronetics Inc.
E 28/100 — 48.5% -35.0% -8.44% $171.4M /stim-vs-ktwo →
PROF
Profound Medical Corp.
D- 40/100 — 70.8% -35.0% +2.44% $240.0M /prof-vs-ktwo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002086524 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) reported GAAP revenue of $317.0K , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, KTWO closed FY2025 with $754.7K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $317.0K $0 — — $754.7K —

3. KTWO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KTWO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, K2 Capital Acquisition Corporation Class A Ordinary Share (NASDAQ: KTWO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $10.11 (+0.20% 1D, market cap $202.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KTWO ranks #200 in composite RQD confidence.

How does KTWO compare to UTMD and PDEX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), KTWO carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, UTMD (Utah Medical Products Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 26.9%, cap $216.7M) and PDEX (Pro-Dex Inc.) posts a D+ grade (54/100 RQD, P/E 22.2x, ROIC 23.2%, cap $186.1M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KTWO?

Per KTWO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002086524), K2 Capital Acquisition Corporation Class A Ordinary Share generated $317.0K in revenue, $0 in net income, and $0 in free cash flow against $754.7K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KTWO trading relative to its 50-day, 200-day, and 52-week technical levels?

KTWO last traded at $10.11 (+0.20% on volume of 528 shares), positioning the stock +0.20% above its 50-day simple moving average ($10.09) and +1.20% above its 200-day simple moving average ($9.99). Across its 52-week range of $9.84 to $10.12, KTWO sits at the 96.4% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±1.8% ($9.93 to $10.29).

Direct Sub-Reports: KTWO RQD Cockpit KTWO 12M Forecast KTWO Earnings & Move KTWO Dividends & DRIP KTWO Insiders & 13F KTWO Whale Options KTWO Profit Sankey KTWO News & Why
ROARABLE RATING BRIEF • RQD 56/100 (D+) ✓ SEC XBRL & RQD VERIFIED

KTWO — K2 Capital Acquisition Corporation Class A Ordinary Share: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) earns a live Roarable RQD composite score of 56/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $10.11 (+0.20% 1D, market capitalization $202.2M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Per the market data, gross, operating, and net margins are each reported as 0%, and the financials section reports FY 2025 revenue as —.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) reported $317.0K in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $754.7K in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 56/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 10/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $9.84 – $10.12 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector is Health Care and industry is Medical/Dental Instruments. No upstream or downstream dependencies, sector correlations, or 2nd-order bottlenecks are identified in the source data.

  • Key Question #1: Can KTWO sustain or expand its — operating margin and — ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $317.0K and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is KTWO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KTWO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KTWO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KTWO Bull vs. Bear Conversation Board — What's Your Call at $10.11?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KTWO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KTWO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $13.22 (+31.0%)
📌 Pinned Debate

Per the Roarable RQD rating, the Forensic Balance Sheet pillar scores 13 of 20 on an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/

Don't sleep on KTWO's setup in Health Care. Per the Roarable RQD rating, the Forensic Balance Sheet pillar scores 13 of 20 on an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (56/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@SiliconVal_Bull Agree on the RQD 56/100 quality, though with 1.0 beta I'm scaling in with half-size at $10.09 and keeping dry powder in case we test $9.38.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $8.07 (-20.0%)
Spot @ $10.09

Per the Roarable RQD rating, the Fundamental Cash Engine pillar scores 10 of 20 with ROIC at 0% and FCF yield at 0%, and the SEC financ

Fading this rally in KTWO at $10.09. Per the Roarable RQD rating, the Fundamental Cash Engine pillar scores 10 of 20 with ROIC at 0% and FCF yield at 0%, and the SEC financials report $0.0M revenue.. With a beta of 1.0 and the stock sitting at $10.09 (52-wk range $9.84–$10.12), the easy multiple expansion is already priced in.

LIVE TAPE